Research Article
Roles of the Immune/Methylation/Autophagy Landscape on Single-Cell Genotypes and Stroke Risk in Breast Cancer Microenvironment
Table 1
Demographics and clinicopathological characteristics of BRCA patients in the TCGA cohort in the high and low BCPRS groups.
| | Variable | BRCA TCGA cohort | | High BCPRS () | Low BCPRS () | value |
| | Survival state | | | Alive | 434(92.93) | 457(97.86) | | | Dead | 33(7.07) | 10(2.14) | | | Follow-up time (day) | | | 0.002 | | Age (year) | | | 0.216 | | T | 0.034 | | T1 | 118(25.27) | 125(26.77) | | | T2 | 266(56.96) | 284(60.81) | | | T3 | 71(15.20) | 42(8.99) | | | T4 | 12(2.57) | 14(3.00) | | | NA | 0(0.00) | 2(0.43) | | | N | 0.007 | | N0 | 220(47.11) | 232(49.68) | | | N1 | 150(32.12) | 154(32.98) | | | N2 | 45(9.64) | 58(12.42) | | | N3 | 43(9.21) | 21(4.50) | | | NA | 9(1.93) | 2(0.43) | | | M | 0.007 | | M0 | 371(79.44) | 406(86.94) | | | M1 | 6(1.28) | 6(1.28) | | | NA | 90(19.27) | 55(11.78) | | | Stage | 0.699 | | Stage I | 76(16.27) | 83(17.77) | | | Stage II | 268(57.39) | 276(59.10) | | | Stage III | 111(23.77) | 96(20.56) | | | Stage IV | 6(1.28) | 4(0.86) | | | Stage X | 6(1.28) | 8(1.71) | | | Race | 0.151 | | Asian | 33(7.07) | 23(4.93) | | | Black or African American | 86(18.42) | 67(14.35) | | | White | 305(65.31) | 331(70.88) | | | NA | 43(9.21) | 46(9.85) | | | Treatment | 0.556 | | Pharmaceutical | 225(48.18) | 234(50.11) | | | Radiation | 242(51.82) | 233(49.89) | | | Immunity groups | 0.001 | | High immunity group | 131(28.05) | 110(23.55) | | | Medium immunity group | 285(61.03) | 267(57.17) | | | Low immunity group | 51(10.92) | 90(19.27) | | | StromalScore | | | | | ImmuneScore | | | | | ESTIMATEScore | | | | | TumorPurity | | | | | mRNAsi | | | | | EREG.mRNAsi | | | 0.126 | | Relative expression of BCRRS-related genes | | HEY1 | | | | | IFNA13 | | | | | NKX2.3 | | | | | NR2F1 | | | | | POU5F1 | | | | | YY1 | | | |
|
|
|
